OSWG推荐的治疗性寡核苷酸的非临床药代动力学(ADME)表征方法。

IF 4 2区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Nucleic acid therapeutics Pub Date : 2023-10-01 Epub Date: 2023-08-17 DOI:10.1089/nat.2023.0011
Cindy L Berman, Madeleine Antonsson, Sandor Batkai, Sieto Bosgra, Girish R Chopda, Wouter Driessen, Jeffrey Foy, Chopie Hassan, Xiao Shelley Hu, Hyun Gyung Jang, Meena, Mark Sanseverino, Thomas Thum, Yanfeng Wang, Martin Wild, Jing-Tao Wu
{"title":"OSWG推荐的治疗性寡核苷酸的非临床药代动力学(ADME)表征方法。","authors":"Cindy L Berman,&nbsp;Madeleine Antonsson,&nbsp;Sandor Batkai,&nbsp;Sieto Bosgra,&nbsp;Girish R Chopda,&nbsp;Wouter Driessen,&nbsp;Jeffrey Foy,&nbsp;Chopie Hassan,&nbsp;Xiao Shelley Hu,&nbsp;Hyun Gyung Jang,&nbsp;Meena,&nbsp;Mark Sanseverino,&nbsp;Thomas Thum,&nbsp;Yanfeng Wang,&nbsp;Martin Wild,&nbsp;Jing-Tao Wu","doi":"10.1089/nat.2023.0011","DOIUrl":null,"url":null,"abstract":"<p><p>This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinical studies. In general, the recommended approach is similar to that for small molecule drugs. However, some differences in timing and/or scope may be warranted due to the greater consistency of results across ON classes as compared with the diversity among small molecule classes. For some types of studies, a platform-based approach may be appropriate; once sufficient data are available for the platform, presentation of these data should be sufficient to support development of additional ONs of the same platform. These recommendations can serve as a starting point for nonclinical study design and foundation for discussions with regulatory agencies.</p>","PeriodicalId":19412,"journal":{"name":"Nucleic acid therapeutics","volume":" ","pages":"287-305"},"PeriodicalIF":4.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561745/pdf/","citationCount":"0","resultStr":"{\"title\":\"OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides.\",\"authors\":\"Cindy L Berman,&nbsp;Madeleine Antonsson,&nbsp;Sandor Batkai,&nbsp;Sieto Bosgra,&nbsp;Girish R Chopda,&nbsp;Wouter Driessen,&nbsp;Jeffrey Foy,&nbsp;Chopie Hassan,&nbsp;Xiao Shelley Hu,&nbsp;Hyun Gyung Jang,&nbsp;Meena,&nbsp;Mark Sanseverino,&nbsp;Thomas Thum,&nbsp;Yanfeng Wang,&nbsp;Martin Wild,&nbsp;Jing-Tao Wu\",\"doi\":\"10.1089/nat.2023.0011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinical studies. In general, the recommended approach is similar to that for small molecule drugs. However, some differences in timing and/or scope may be warranted due to the greater consistency of results across ON classes as compared with the diversity among small molecule classes. For some types of studies, a platform-based approach may be appropriate; once sufficient data are available for the platform, presentation of these data should be sufficient to support development of additional ONs of the same platform. These recommendations can serve as a starting point for nonclinical study design and foundation for discussions with regulatory agencies.</p>\",\"PeriodicalId\":19412,\"journal\":{\"name\":\"Nucleic acid therapeutics\",\"volume\":\" \",\"pages\":\"287-305\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561745/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nucleic acid therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/nat.2023.0011\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/8/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nucleic acid therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/nat.2023.0011","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本白皮书总结了寡核苷酸安全工作组的吸收、分布、代谢和排泄(ADME)小组委员会关于非临床研究中寡核苷酸(ON)疗法的吸收、分配、代谢和排放特性的建议。一般来说,推荐的方法与小分子药物的方法相似。然而,由于与小分子类别之间的多样性相比,ON类别之间的结果具有更大的一致性,因此可能需要在时间和/或范围上存在一些差异。对于某些类型的研究,基于平台的方法可能是合适的;一旦平台有足够的数据可用,这些数据的呈现就应该足以支持同一平台的其他ON的开发。这些建议可以作为非临床研究设计的起点和与监管机构讨论的基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides.

This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinical studies. In general, the recommended approach is similar to that for small molecule drugs. However, some differences in timing and/or scope may be warranted due to the greater consistency of results across ON classes as compared with the diversity among small molecule classes. For some types of studies, a platform-based approach may be appropriate; once sufficient data are available for the platform, presentation of these data should be sufficient to support development of additional ONs of the same platform. These recommendations can serve as a starting point for nonclinical study design and foundation for discussions with regulatory agencies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nucleic acid therapeutics
Nucleic acid therapeutics BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
7.60
自引率
7.50%
发文量
47
审稿时长
>12 weeks
期刊介绍: Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.
期刊最新文献
It is Time to Revisit miRNA Therapeutics. Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides. Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity. Levels of Exon-Skipping Are Not Artificially Overestimated Because of the Increased Affinity of Tricyclo-DNA-Modified Antisense Oligonucleotides to the Target DMD Exon. Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1